Last --
Change Today 0.00 / 0.00%
Volume 0.0
2914 On Other Exchanges
Symbol
Exchange
2914 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

japan tobacco inc (2914) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for JAPAN TOBACCO INC (2914)

Related News

No related news articles were found.

japan tobacco inc (2914) Related Businessweek News

View More BusinessWeek News

japan tobacco inc (2914) Details

Japan Tobacco Inc., together with its subsidiaries, manufactures and sells tobacco products, primarily cigarettes in Japan and internationally. The company operates through five segments: Domestic Tobacco Business, International Tobacco Business, Pharmaceutical Business, Beverage Business, and Processed Food Business. It is also involved in the import and distribution of tobacco products. The company offers its tobacco products primarily under the Mild Seven, MEVIUS, Seven Stars, Pianissimo, Zerostyle, Winston, Camel, Benson & Hedges, Silk Cut, LD, Sobranie, Ploom, and Glamour brand names. In addition, it is engaged in the research and development, manufacture, and sale of prescription drugs. The company’s principal pharmaceutical products comprise Remitch capsules; Truvada combination tablets; Riona tablets; Cedartolen Sublingual Drop–Japanese Cedar Pollen, an immunotherapy drug; and Stribild combination tablets. Further, it manufactures and sells beverages, including canned coffee under the Roots brand and natural water under the Momono Tennen-sui brand; staple food products comprising frozen noodles, frozen rice, packed cooked rice, and frozen baked bread; bakery products; and seasonings, as well as operates vending machines for beverage products. Japan Tobacco Inc. was founded in 1898 and is headquartered in Tokyo, Japan.

Founded in 1898

japan tobacco inc (2914) Top Compensated Officers

Chief Executive Officer, President, Represent...
Total Annual Compensation: ¥108.0M
Compensation as of Fiscal Year 2014.

japan tobacco inc (2914) Key Developments

Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. Sign Agreement to Market Two New Tenofovir Alafenamide Based Anti HIV Drugs in Japan

Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. announced that they have signed an agreement to market two new tenofovir alafenamide (TAF)-based anti-HIV drugs, for which JT holds the exclusive rights to develop and commercialize in Japan. Under the terms of the agreement, Torii holds exclusive rights to market the drugs in Japan, subsequent to JT's obtaining manufacturing and marketing approval from the country's authorities. TAF is a novel prodrug of tenofovir, a nucleotide reverse transcriptase inhibitor (NRTI) discovered by Gilead Sciences Inc. (Gilead). Previously, only a prodrug of tenofovir, tenofovir disoproxil fumarate (TDF) has been available in the market as an active ingredient of Viread®, Truvada® and Stribild®. TAF has demonstrated high antiviral efficacy at a dose 10 times lower than TDF. It is also expected that influence on kidneys and bones can be reduced with TAF compared to TDF. JT is currently preparing to file its New Drug Application (NDA) in Japan for an investigational once-daily single tablet regimen (E/C/F/TAF) containing elvitegravir 150mg, cobicistat 150mg, emtricitabine 200mg and TAF 10mg, one of the two TAF-based drugs pertaining to the agreement. E/C/F/TAF is an antiretroviral which can treat HIV infection with once-daily administration. TDF 300mg, one of four ingredients of Stribild® Combination Tablets which has been marketed by Torii in Japan from 2013, is replaced with TAF 10mg to compose E/C/F/TAF. In Gilead's two Phase 3 studies, E/C/F/TAF showed high efficacy and good tolerability comparable to Stribild®, a comparator of the studies. Significantly better renal and bone laboratory parameters were also observed when compared with Stribild®. Gilead has submitted an NDA to the U.S. Food and Drug Adminstration (FDA) and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for E/C/F/TAF. The other TAF-based drug comprises emtricitabine and TAF (F/TAF). TDF, one of two active ingredients of Truvada®, is replaced with TAF to compose F/TAF. Gilead is conducting a Phase 3 study for F/TAF and plans to submit regulatory applications in the U.S. and EU in Second Quarter of 2015. JT plans to submit its NDA in Japan for F/TAF upon Gilead's obtaining approval outside Japan.

Japan Tobacco Seeks Acquisitions

Mitsuomi Koizumi, President of Japan Tobacco Inc. (TSE:2914) said earlier this month that the company will speed up deals relating to other types of tobacco products, such as e-cigarettes. It is also interested in acquisitions in countries where it doesn't have much presence such as Brazil, Singapore and Bangladesh.

Japan Tobacco Inc. Reports Sales Results for the Month of January 2015

Japan Tobacco Inc. reported preliminary Japanese domestic cigarette sales results for month of January 2015. For the month, the company reported cigarettes sales volume of 8.3 billion compared to 8.8 billion for the same period a year ago. Japanese domestic cigarette revenue was JPY 46.8 billion compared to JPY 48.3 billion a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
2914:JP ¥3,810.00 JPY -4.50

2914 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Altria Group Inc $55.88 USD -0.58
British American Tobacco PLC 3,813 GBp +46.00
Imperial Tobacco Group PLC 3,226 GBp +29.00
Kirin Holdings Co Ltd ¥1,596 JPY 0.00
Reynolds American Inc $74.55 USD -0.87
View Industry Companies
 

Industry Analysis

2914

Industry Average

Valuation 2914 Industry Range
Price/Earnings 16.0x
Price/Sales 2.5x
Price/Book 2.7x
Price/Cash Flow 15.2x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAPAN TOBACCO INC, please visit www.jt.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.